Middle East & Africa Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)

https://marketpublishers.com/r/M440CF5165EDEN.html
Date: January 2026
Pages: 218
Price: US$ 3,450.00 (Single User License)
ID: M440CF5165EDEN

Abstracts

The Middle East & Africa Anti-Obesity Drugs Market is projected to grow significantly, reaching approximately US$ 1,064.3 million by 2031, up from US$ 270.8 million in 2024, with an estimated compound annual growth rate (CAGR) of 22.3% from 2025 to 2031.

Executive Summary and Market Analysis

The anti-obesity drugs market in the Middle East & Africa is divided into key regions including the UAE, Saudi Arabia, South Africa, and the broader Middle East & Africa. Factors such as increased suburbanization and lifestyle changes have led to a rise in the consumption of high-calorie processed foods and a decrease in physical activity, resulting in higher obesity rates. Additionally, there is a growing awareness of the health risks associated with obesity, such as diabetes, cardiovascular diseases, and certain cancers, which has spurred demand for medical treatments. Governments and health organizations are launching public health initiatives to combat obesity, further driving market growth. Enhanced access to healthcare, rising disposable incomes, and increased investment in healthcare infrastructure are also contributing to this expansion. Moreover, the presence of pharmaceutical companies offering innovative anti-obesity treatments, particularly GLP-1 receptor agonists, is on the rise. As cultural attitudes evolve and medical tourism becomes more prevalent, especially in countries like the UAE and South Africa, the anti-obesity drug market is expected to continue its upward trajectory.

Strategic Insights

Market Segmentation Analysis

By Type: The market is categorized into Prescription Drugs and OTC Drugs, with Prescription Drugs holding the largest market share in 2024.

By Mechanism of Action: Segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others, with Centrally Acting Drugs leading in market share in 2024.

By Drug Class: Includes GLP-1 Agonists, Lipase Inhibitors, MC4R Agonists, and Others, where GLP-1 Agonists dominated in 2024.

By GLP-1 Agonist: Further divided into Semaglutide, Liraglutide, and Tirzepatide (Zepbound), with Semaglutide being the most prominent in 2024.

By Application: Categories include Appetite Suppression, Inhibition of Fat Absorption, Metabolic Enhancement, and Combination, with Appetite Suppression leading the market.

By Route of Administration: The market is segmented into Oral and Parenteral, with Oral being the most common route in 2024.

By Distribution Channel: Includes Hospital Pharmacies, Online Channels, and Retail Pharmacies, with Hospital Pharmacies holding the largest share.

Market Outlook

Obesity is influenced by genetic, environmental, and lifestyle factors. Recent advancements indicate that individuals respond differently to anti-obesity medications based on their genetic profiles, metabolic rates, gut microbiota, and existing health conditions. This variability means that a medication effective for one patient may not work for another. Precision medicine is emerging in obesity treatment, utilizing pharmacogenomic testing and detailed patient profiling to identify the most effective drug or combination of drugs for each individual. Companies are developing diagnostic tools to analyze genetic markers related to obesity and drug metabolism, aiding clinicians in predicting patient responses to various treatments. The expanding pipeline of anti-obesity drugs targeting different mechanisms allows for tailored therapies that align with individual patient needs. For instance, if a patient does not respond well to a GLP-1 agonist, a physician may consider switching to or combining it with another agent targeting a different pathway.

+357 96 030922
info@marketpublishers.com

Pharmacogenomic companies like Acosta and Phenomix are providing tests that support personalized obesity treatment, a trend expected to accelerate as more data and drugs become available. This shift towards individualized treatment regimens is anticipated to enhance the effectiveness, cost-efficiency, and acceptance of anti-obesity pharmacotherapy among patients and healthcare providers. In March 2025, VIVUS LLC launched QSYMIA® (phentermine and topiramate extended-release capsules) in the UAE, marking a significant step in addressing the region's rising obesity rates, projected to affect over 7.5 million people by 2035.

Country Insights

The market is further segmented by country, with Saudi Arabia holding the largest share in 2024. The prevalence of overweight and obesity in Saudi Arabia has nearly doubled over the past fifty years, with over half the population classified as overweight and more than 20% as obese. The economic burden of obesity management in the country is estimated at US$ 6.4 billion, underscoring the urgent need for effective interventions. The Saudi government has implemented various policies under its Vision 2030 plan to promote a healthier population.

In April 2025, Novo Nordisk signed a Memorandum of Understanding with Lifera to localize the manufacturing of semaglutide-based GLP-1 treatments in Saudi Arabia, enhancing the country's healthcare infrastructure. This agreement aims to launch Wegovy in Saudi Arabia, making it accessible to patients in both public and private sectors, reflecting the country's commitment to tackling obesity.

Company Profiles

Key players in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence.

Contents

7. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE

8. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION

9. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS

11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

12. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION

12.1 Oral
12.1.1 Overview
12.1.2 Oral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

13. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL

13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

14. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS

+357 96 030922
info@marketpublishers.com

17 COMPANY PROFILES

18. APPENDIX

18.1 About The Insight Partners

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Middle East & Africa Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)

Product link: https://marketpublishers.com/r/M440CF5165EDEN.html

Price: US$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M440CF5165EDEN.html